Company: DNLI
Filing Date: 2025-02-27
Form Type: S-3ASR
Source: 0001628280-25-008647
Chunk: 10

Company: Denali Therapeutics Inc.
Filing Date: 2025-02-27
Form: S-3ASR
Chunk 10
---
 of the common stock on our behalf, the sales agents will each be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of the sales agents will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to the sales agents with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act.

Investing in our common stock involves a high degree of risk. See “ Risk Factors ” on page S- 5 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement before investing in our common stock.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

#### ___________________

| Goldman Sachs & Co. LLC |     | Leerink Partners |

#### Prospectus supplement dated February 27, 2025.

### TABLE OF CONTENTS
|                                                                                          |     | Page |
| ABOUT THIS PROSPECTUS SUPPLEMENT                                                         |     | S-i  |
| PROSPECTUS SUPPLEMENT SUMMARY                                                            |     | S-1  |
| THE OFFERING                                                                             |     | S-3  |
| RISK FACTORS                                                                             |     | S-5  |
| SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS                                        |     | S-7  |
| USE OF PROCEEDS                                                                          |     | S-9  |
| DILUTION                                                                                 |     | S-10 |
| DESCRIPTION OF CAPITAL STOCK                                                             |     | S-12 |
| MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS OF OUR COMMON STOCK |     | S-16 |
| PLAN OF DISTRIBUTION                                                                     |     | S-20 |
| LEGAL MATTERS                                                                            |     | S-21 |
| EXPERTS                                                                                  |     | S-21 |
| WHERE YOU CAN FIND MORE INFORMATION                                                      |     | S-21 |

We have not, and the sales agents have not, authorized anyone to provide you with different information than that contained in or incorporated by reference in this prospectus supplement, the accompanying prospectus, and in any free writing prospectus that we have authorized for use in connection with this offering. We are not, and the sales agents are not, making an offer to sell these securities in any jurisdiction where the offer or